Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715104 · ClinicalTrials.gov registry record · Phase 2
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
A Phase 2 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00715104: Completed Phase 2 study, sponsored by Dendreon.
NCT00715104 is a Phase 2 study that has completed, run by Dendreon. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00715104, a Phase 2 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is an open label, Phase 2 trial of immunotherapy with sipuleucel-T as neoadjuvant treatment in men with localized prostate cancer.
Primary Outcome
CD3+ T cell infiltration within prostate tissue was quantified using immunohistochemistry (IHC) staining techniques. Cells were enumerated per unit area (cells/μm2). For post-RP tissue specimens, three areas of interest were identified: Benign tissue, tumor tissue, and tumor interface tissue.
Interventions
- BIOLOGICAL Sipuleucel-T with Booster
- BIOLOGICAL Sipuleucel-T without Booster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT00715104 record still lists
NCT00715104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Sipuleucel-T with Booster is the first listed.
NCT00715104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00715104 about?
NCT00715104 is a clinical study titled "Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer". This is an open label, Phase 2 trial of immunotherapy with sipuleucel-T as neoadjuvant treatment in men with localized prostate cancer.
What is the current status of trial NCT00715104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2008-07. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00715104?
The interventions under investigation include: Sipuleucel-T with Booster (BIOLOGICAL), Sipuleucel-T without Booster (BIOLOGICAL).
Who is sponsoring clinical trial NCT00715104?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00715104's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia